Hansson, Oskar
Svensson, Martina
Gustavsson, Anna-Märta
Andersson, Emelie
Yang, Yiyi
Nägga, Katarina
Hållmarker, Ulf
James, Stefan
Deierborg, Tomas
Funding for this research was provided by:
Swedish Alzheimer foundation (0)
Hjärnfonden (0)
European Research Council (0)
Vetenskapsrådet (0)
Knut och Alice Wallenbergs Stiftelse (0)
Demensförbundet (0)
Article History
Received: 26 March 2019
Accepted: 10 September 2019
First Online: 20 October 2019
Ethics approval and consent to participate
: The Ethical Review Board in Uppsala, Sweden, approved the Vasaloppet study (2010, Dnr 2010/305). The Regional Ethical Review Board of Lund University gave ethical approval for the Malmo Diet and Cancer Study in several stages (2002, Dnr 244-02, 2004, Dnr 154-2004, 2009, Dnr 633-2009, 2011, Dnr 83-2011, and 2013, Dnr 489-2013.) All MDCS participants provided informed consent at the study entry, when no cognitive disorder was present/diagnosed. Animal experiments were approved by Malmö/Lund animal ethics committee (2012, Dnr: M427-12) and performed in accordance to the Directive of the European Parliament.
: Not applicable
: Oskar Hansson acquired research support (for the institution) from Roche, GE Healthcare, Biogen, AVID Radiopharmaceuticals, Fujirebio, and Euroimmun. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Biogen, Roche, and Fujirebio. The remaining authors declare that they have no competing interests.